Were Analysts Bearish AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) This Week?

July 13, 2018 - By Eula Gilbert

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) LogoInvestors sentiment decreased to 0.84 in Q1 2018. Its down 0.06, from 0.9 in 2017Q4. It turned negative, as 27 investors sold AMAG Pharmaceuticals, Inc. shares while 55 reduced holdings. 32 funds opened positions while 37 raised stakes. 37.48 million shares or 0.65% less from 37.72 million shares in 2017Q4 were reported.
Daiwa Securities Gp holds 195 shares or 0% of its portfolio. Howe Rusling, a New York-based fund reported 202 shares. Glenmede Na has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). The New York-based Alliancebernstein Limited Partnership has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). State Of Tennessee Treasury Department, Tennessee-based fund reported 25,328 shares. Northern invested in 458,445 shares or 0% of the stock. Teachers Retirement Systems Of The State Of Kentucky holds 8,631 shares or 0% of its portfolio. California Public Employees Retirement System holds 96,339 shares or 0% of its portfolio. Strs Ohio, Ohio-based fund reported 40,900 shares. Principal Financial Group holds 0.01% or 267,631 shares in its portfolio. J Goldman Communications Ltd Partnership has 151,378 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 1,049 shares. Federated Invsts Pa reported 81,460 shares. Riverhead Cap Mgmt Limited Liability Corporation stated it has 4,983 shares. Moreover, Livforsakringsbolaget Skandia Omsesidigt has 0.33% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Since February 23, 2018, it had 0 insider buys, and 2 insider sales for $516,016 activity. $16,016 worth of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was sold by Vittiglio Joseph on Friday, February 23.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 8 analysts covering Amag Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Amag Pharmaceuticals had 19 analyst reports since January 18, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Hold” rating in Wednesday, February 14 report. The company was maintained on Monday, June 25 by Cantor Fitzgerald. FBR Capital maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rating on Friday, March 23. FBR Capital has “Hold” rating and $2300 target. The rating was maintained by Cantor Fitzgerald on Thursday, May 3 with “Hold”. As per Thursday, February 15, the company rating was maintained by Jefferies. As per Monday, March 5, the company rating was downgraded by Jefferies. On Thursday, January 18 the stock rating was maintained by Piper Jaffray with “Hold”. Cantor Fitzgerald maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Sunday, June 17 with “Hold” rating. The company was upgraded on Thursday, February 15 by Janney Capital. The stock has “Overweight” rating by Morgan Stanley on Wednesday, February 28. Below is a list of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) latest ratings and price target changes.

25/06/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0000 Maintain
17/06/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0000 Maintain
15/06/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $23 New Target: $30 Upgrade
15/06/2018 Broker: Janney Capital Old Rating: Buy New Rating: Neutral New Target: $20 Downgrade
04/06/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0000 Maintain
21/05/2018 Broker: Leerink Swann Rating: Hold New Target: $26.0000 Initiate
03/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0000 Maintain
23/03/2018 Broker: FBR Capital Rating: Hold New Target: $23.0000 Maintain
05/03/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
27/02/2018 Broker: Cowen & Co Rating: Hold New Target: $25.0 Maintain

The stock decreased 0.57% or $0.125 during the last trading session, reaching $21.875. About 408,473 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 30.22% since July 13, 2017 and is uptrending. It has outperformed by 17.65% the S&P500.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $750.89 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

More news for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were recently published by: Globenewswire.com, which released: “Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton …” on June 18, 2018. Nasdaq.com‘s article titled: “AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®” and published on June 15, 2018 is yet another important article.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.